Haleon plc (NYSE: HLN) prices $2B multi‑tranche bond to target 2027 notes
Rhea-AI Filing Summary
Haleon plc reports that its wholly owned subsidiary, Haleon Capital LLC, has launched and priced a $2 billion SEC‑registered, fixed‑rate USD bond offering across three senior tranches, scheduled to settle on 21 August 2026. The tranches comprise $600,000,000 notes due 2029 with a 4.625% coupon, $600,000,000 notes due 2031 with a 4.875% coupon, and $800,000,000 notes due 2036 with a 5.375% coupon. Principal and interest on all notes are fully and unconditionally guaranteed by Haleon plc.
The company expects to use the net proceeds, together with cash on hand if required, to repurchase in whole or in part $1,999,350,000 of its outstanding 3.375% Fixed Rate Senior Notes due March 2027 via a concurrent tender offer announced on 11 August 2026, and for general corporate purposes. Barclays, BofA Securities, Deutsche Bank Securities, Goldman Sachs and Mizuho served as joint book‑running managers. The announcement includes standard securities law legends and a cautionary note on forward‑looking statements.
Positive
- None.
Negative
- None.
Key Figures
Total bond offering size: $2,000,000,000
2029 notes tranche: $600,000,000 at 4.625%
2031 notes tranche: $600,000,000 at 4.875%
+3 more
6 metrics
Total bond offering size
$2,000,000,000
Aggregate principal amount of three‑tranche SEC‑registered bond offering
2029 notes tranche
$600,000,000 at 4.625%
Senior fixed rate notes maturing in 2029
2031 notes tranche
$600,000,000 at 4.875%
Senior fixed rate notes maturing in 2031
2036 notes tranche
$800,000,000 at 5.375%
Senior fixed rate notes maturing in 2036
Targeted 2027 notes
$1,999,350,000 at 3.375%
Outstanding Fixed Rate Senior Notes due March 2027 subject to tender offer
Settlement date
21 August 2026
Scheduled settlement date for the three‑tranche bond offering
Key Terms
senior fixed rate notes, tender offer, fully and unconditionally guaranteed, prospectus supplement, +1 more
5 terms
senior fixed rate notes financial
"senior fixed rate notes with a coupon of 4.625% maturing in 2029"
tender offer financial
"outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027 in the concurrent tender offer"
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
fully and unconditionally guaranteed financial
"Payment of principal and interest is fully and unconditionally guaranteed by Haleon plc"
prospectus supplement regulatory
"solely by means of a prospectus supplement to the prospectus included in the registration statement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
forward-looking statements regulatory
"Certain statements contained in this announcement are, or may be deemed to be, "forward-looking statements""
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What bond offering did Haleon plc (HLN) announce in August 2026?
Haleon plc announced a $2 billion SEC‑registered bond offering via Haleon Capital LLC, split into three tranches maturing in 2029, 2031 and 2036, all carrying fixed coupons and fully guaranteed by Haleon.
What are the coupon rates and maturities of Haleon (HLN)'s new notes?
The new senior notes carry coupons of 4.625% due 2029, 4.875% due 2031 and 5.375% due 2036. Each tranche is USD‑denominated and forms part of a $2 billion SEC‑registered bond issuance.
How will Haleon (HLN) use the proceeds from the $2 billion bond issue?
Haleon expects to use net proceeds, with cash on hand if necessary, to repurchase up to $1,999,350,000 of its 3.375% Senior Notes due March 2027 in a concurrent tender offer and for general corporate purposes.
Who guarantees the new Haleon (HLN) senior fixed rate notes?
Payment of principal and interest on the new notes is fully and unconditionally guaranteed by Haleon plc, providing support from the parent company for the obligations of Haleon Capital LLC as issuer.
Which banks acted as joint book‑running managers for Haleon (HLN)'s bond deal?
The joint book‑running managers were Barclays Capital Inc., BofA Securities, Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and Mizuho Securities USA LLC, coordinating the $2 billion bond offering.
What existing Haleon (HLN) debt is targeted by the concurrent tender offer?
The concurrent tender offer targets Haleon Capital LLC’s outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027, which the company may repurchase in whole or in part using proceeds from the new bond issuance.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
13
August 2026 - “Launch &
price: $2bn three-tranche bond offering”
|
99.1
Haleon launches and prices
three‐tranche,
$2 billion fixed rate USD denominated bonds
13 August 2026: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces
that on 12 August 2026, its wholly-owned subsidiary, Haleon US
Capital LLC (the "Issuer"), launched and priced a $2bn
SEC-registered bond offering (the "Offering"), consisting of the
following notes. The Offering is scheduled to settle on 21 August
2026.
●
$600,000,000 of senior fixed rate notes with a
coupon of 4.625% maturing in 2029;
●
$600,000,000 of senior fixed rate notes with a
coupon of 4.875% maturing in 2031; and
●
$800,000,000 of senior fixed rate notes with a
coupon of 5.375% maturing in 2036.
(collectively, the "Notes")
Payment of principal and interest is fully and unconditionally
guaranteed by Haleon plc. The Company expects to use the net
proceeds of the Offering together with cash on hand, if necessary,
to repurchase in whole or
in part the Issuer's outstanding $1,999,350,000 3.375% Fixed Rate
Senior Notes due March 2027 in the concurrent tender offer
announced on 11 August 2026, and for general purposes of the
Company and its subsidiaries.
Barclays Capital Inc., BofA Securities, Inc., Deutsche Bank
Securities Inc., Goldman Sachs & Co. LLC and Mizuho Securities
USA LLC acted as Joint Book-Running Managers on the
Offering.
This announcement is not an offer to purchase or a solicitation of
an offer to sell any of the notes subject to the concurrent tender
offer and shall not constitute an offer to sell or the solicitation
of an offer to buy the Notes either in the United States or any
other jurisdiction, nor shall there be any sale of Notes in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration and qualification under the
securities laws of any such jurisdiction. Any public offering of
Notes in the United States is being made solely by means of a
prospectus supplement to the prospectus included in the
registration statement filed with the SEC by Haleon plc, Haleon US
Capital LLC and Haleon UK Capital plc.
The Issuer and the Company have filed a registration statement
(File Nos. 333-297789 and 333-297789-02), including a prospectus
and a preliminary prospectus supplement, with the SEC for the
Offering to which this communication relates. Investors should read
the preliminary prospectus supplement and the prospectus in that
registration statement and other documents the Issuer and the
Company have filed with the SEC for more complete information about
the Issuer, the Company and this Offering. These documents may be
obtained for free by visiting EDGAR on the SEC website at
www.sec.gov. Alternatively, the Issuer, the Company, any
underwriter or any dealer participating in the Offering will
arrange to send the prospectus and the preliminary prospectus
supplement if requested by calling Barclays Capital Inc. toll-free
at 1-888-603-5847; BofA Securities, Inc. toll-free at
1-800-294-1322; Deutsche Bank Securities Inc. toll-free at
1-800-503-4611; Goldman Sachs & Co. LLC toll-free at
1-866-471-2526; or Mizuho Securities USA LLC toll-free at
1-866-271-7403.
Cautionary note regarding forward-looking statements
Certain statements contained in this announcement are, or may be
deemed to be, "forward-looking statements" (including for purposes
of the safe harbor provisions for forward-looking statements
contained in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934). Forward-looking
statements give Haleon's current expectations and projections about
future events, including strategic initiatives and future financial
condition and performance, and so Haleon's actual results may
differ materially from what is expressed or implied by such
forward-looking statements. Forward-looking statements sometimes
use words such as "expects," "anticipates," "believes," "targets,"
"plans," "intends," "aims," "projects," "indicates," "may,"
"might," "will," "should," "potential," "could" and words of
similar meaning (or the negative thereof). All statements, other
than statements of historical facts, included in this announcement
are forward-looking statements. Such forward-looking statements
include, but are not limited to, statements relating to future
actions, including the use of proceeds from the Offering,
prospective products or product approvals, delivery on strategic
initiatives (including but not limited to acquisitions,
realizations of efficiencies and responsible business goals),
future performance or results of current and anticipated products,
sales efforts, expenses, the outcome of contingencies such as legal
proceedings, dividend payments and financial results.
Any forward-looking statements made by or on behalf of Haleon speak
only as of the date they are made and are based upon the knowledge
and information available to Haleon on the date of this
announcement. These statements and views may be based on a number
of assumptions and, by their nature, involve known and unknown
risks, uncertainties and other factors because they relate to
events and depend on circumstances that may or may not occur in the
future and/or are beyond Haleon's control or precise estimate.
Subject to our obligations under English and U.S. law in relation
to disclosure and ongoing information, we undertake no obligation
to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Enquiries
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Gemma
Thomas
|
+44 7985 175048
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
|
|
|
||
|
Treasury
|
|
||
|
Mike
Rowe
|
+44
7775 012365
|
|
|
|
Ben
Checkland
|
+44
7823 370368
|
|
|
|
Email: cf-treasury@haleon.com
|
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
August 13, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|